Table 1.
Summary of AUTO2 patient demographics
| Total treated | 11 |
| Sex | |
| Male | 8 (72.7%) |
| Female | 3 (27.4%) |
| Age (median/range) | 61(45–69) |
| Isotype | |
| IgG | 9 (81.8%) |
| LC | 2 (18.2%) |
| ISS at presentation | |
| I | 6 (54.5%) |
| II | 1 (9.1%) |
| III | 3 (27.3%) |
| Unknown | 1 (9.1%) |
| Cytogenetics | |
| High risk | 4 (36.4%) |
| Standard risk | 2 (18.2%) |
| Unknown | 5 (45.5%) |
| Years since diagnosis (median/range) | 6 (1–11) |
| Extramedullary disease | 3 (27.3%) |
| Previous therapy | |
| Lines (medium/range) | 5 (3–6) |
| Previous ASCT | 6 (54.5%) |
| Anti CD38 exposed | 6 (54.5%) |
| Progressed on last line | 5 (45.5%) |
| Refractory to PI or IMID | 11 (100%) |
| Refractory to anti CD38 | 5 (45.5%) |
| Double refractory (PI and IMID) | 9 (81.8%) |
| Triple refractory (PI, IMID, CD38) | 3 (27.3%) |
Refractory, progressed on or within 60 days of receiving these agents. High risk cytogenetics defined as t(4;14), t(14;16), t(14;20), del(17p), 1q gain, 1p loss.
ASCT, autologous stem cell transplant; IMID, immunomodulatory imide; ISS, International Staging System; LC, Light Chain; PI, proteasome inhibitor.